Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways
The Prostate · 2026
DOI: 10.1002/pros.70098 ↗At a glance
Multizentrische Studie in The Prostate, 2026. Written by Yusuf Ilhan and 10 co-authors. Institution: Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey. Major MEDLINE topics: Prostate-Specific Antigen, Androgen Receptor Antagonists, Phenylthiohydantoin, Prostatic Neoplasms, Castration-Resistant. Cited 1 times so far (Crossref); 16 references. Funded by: The authors received no specific funding for this work..
Topics: Onkologische Pflege
Abstract (original language)
Background
The prognostic value of the PSA ELIMination rate constant K (PRO‐KELIM) score was investigated in patients with metastatic castration‐sensitive prostate cancer (mCSPC) treated with novel androgen receptor inhibitors.
Methods
This multicenter retrospective study included 160 patients diagnosed with prostate adenocarcinoma between 2011 and 2024 who received enzalutamide or abiraterone during the mCSPC and had at least three PSA measurements within the first 100 days of treatment. The patients were categorized into favorable (PRO‐KELIM ≥ 1.0) and unfavorable (PRO‐KELIM < 1.0) groups. Progression‐free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier survival analysis and Cox regression.
Results
Median PFS was significantly higher in the favorable group than in the unfavorable group (not reached vs. 40.0 months, p < 0.001). The estimated 2‐year PFS rates in the favorable and unfavorable groups were 78% and 52%, respectively. In multivariate analyses, a high PRO‐KELIM score (HR 2.99; 95% CI 1.35–6.66, p = 0.007) and good initial response to treatment ( p = 0.001) were independent favorable prognostic factors for PFS. The median OS did not differ significantly between the groups ( p = 0.27). PRO‐KELIM score was not an independent prognostic factor for OS ( p = 0.76).
Conclusion
These findings suggest that the PRO‐KELIM score can be a valuable prognostic tool in the mCSPC to assess early treatment response and predict disease progression.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey.
- Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey.
- Department of Medical Oncology, Kayseri Acıbadem Hospital, Kayseri, Turkey.
- Department of Medical Oncology, Van Yüzüncü Yıl University, Van, Turkey.
- Alanya District Health Directorate, Alanya, Antalya, Turkey.
- Department of Medical Oncology, Alaaddin Keykubat University, Antalya, Turkey.
ORCID profiles: Yusuf Ilhan, Murat Araz, Ali Fuat Gurbuz, Semiha Urvay, Muslih Urun, Berrak Mermit Ercek, Ozden Ozilice, Onur Yazdan Balcik, Canan Yildiz, Hacer Demir, Ismail Beypinar
Funding
- The authors received no specific funding for this work.
Cite
APA
Ilhan, Y., Araz, M., Gurbuz, A. F., Urvay, S., Urun, M., Mermit Ercek, B., Ozilice, O., Balcik, O. Y., Yildiz, C., Demir, H., & Beypinar, I. (2026). Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways. The Prostate. https://doi.org/10.1002/pros.70098
Vancouver
Ilhan Y, Araz M, Gurbuz AF, Urvay S, Urun M, Mermit Ercek B, et al. Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways. The Prostate. 2026. doi:10.1002/pros.70098
BibTeX
@article{Ilhan2026,
author = {Ilhan, Yusuf and Araz, Murat and Gurbuz, Ali Fuat and Urvay, Semiha and Urun, Muslih and Mermit Ercek, Berrak and Ozilice, Ozden and Balcik, Onur Yazdan and Yildiz, Canan and Demir, Hacer and Beypinar, Ismail},
title = {Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70098}
}
EUVIMED